NCT05969054View on ClinicalTrials.gov

Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy

PHASE4RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Alzheimer Disease 3Epilepsy
Interventions
DRUG

Lacosamide 100 mg

Subjects who were randomly divided into group A took lacosamide for 6 months during treatment (initial dose was 50mg bid, maintained for one week and then increased to 100mg bid and maintained at this dose)

DRUG

Levetiracetam 250mg

Subjects randomly divided into group B took levetiracetam for 6 months during treatment (initial dose was 250mg bid, maintained for one week and then increased to 500mg bid and maintained at this dose).

Trial Locations (1)

410008

RECRUITING

Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Xiangya Hospital of Central South University

OTHER